Heart Failure Clinical Trials in San Francisco, California

17 studies are recruiting for heart failure in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Alleviant ALLAY-HFrEF Study

   Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   68 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT06812533 on ClinicalTrials.gov

2. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, San Francisco, California

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

3. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

   Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   San Francisco, CA Investigative Site 10023, San Francisco, California

   Locations

   356 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06008197 on ClinicalTrials.gov

4. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

   Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   San Francisco, CA Investigative Site CON-10315, San Francisco, California

   Locations

   140 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06024746 on ClinicalTrials.gov

5. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   California Pacific Medical Center Van Ness Campus, San Francisco, California

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

6. Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

   Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Zuckerberg San Francisco General, San Francisco, California

   Locations

   50 in total

   Run by

   Procyrion

   See if you can join NCT05677100 on ClinicalTrials.gov

7. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kaiser Permanente Northern California, San Francisco, California

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

8. Alleviant ALLAY-HF Study

   Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

   Stage

   Not phased

   Ages

   40 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   93 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT05685303 on ClinicalTrials.gov

9. Assessment of CCM in HF With Higher Ejection Fraction

   The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   105 in total

   Run by

   Impulse Dynamics

   See if you can join NCT05064709 on ClinicalTrials.gov

10. A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

    This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…

    Stage

    Phase 2

    Ages

    40 to 84

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    117 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT06979362 on ClinicalTrials.gov

11. A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

    Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

    Stage

    Phase 3

    Ages

    18 and older

    Site

    San Francisco, CA Investigative Site FIN-10023, San Francisco, California

    Locations

    176 in total

    Run by

    Colorado Prevention Center

    See if you can join NCT06033950 on ClinicalTrials.gov

12. PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

    This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UCSF Medical Center, San Francisco, California

    Locations

    48 in total

    Run by

    Endotronix, Inc.

    See if you can join NCT05934487 on ClinicalTrials.gov

13. Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

    The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California at San Francisco, San Francisco, California

    Locations

    68 in total

    Run by

    Abbott Medical Devices

    See if you can join NCT06526195 on ClinicalTrials.gov

14. The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

    The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California- San Francisco, San Francisco, California

    Locations

    92 in total

    Run by

    Cardiac Dimensions, Inc.

    See if you can join NCT03142152 on ClinicalTrials.gov

15. Voice Analysis to Detect Pulmonary Arterial Pressure Changes in Heart Failure

    VAPP-HF is a prospective, multi-center, observational study assessing whether daily voice recordings analyzed by a machine learning algorithm can detect changes in pulmonary arterial (PA) pressure in heart failure patients with implanted PA pressure sensors (e.g., CardioMEMS, Cordella). Patients ac…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco (UCSF), San Francisco, California

    Locations

    3 in total

    Run by

    Noah Labs

    See if you can join NCT07443670 on ClinicalTrials.gov

16. AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM

    Study Design: This is an international, multicenter, observational, non-interventional, prospective, blinded, single-arm, two-period study, to collect patient utterances that will be retrospectively analyzed to determine the sensitivity and UPNR of the HearO system.

    Stage

    Not phased

    Ages

    22 and older

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    45 in total

    Run by

    Cordio Medical

    See if you can join NCT06378632 on ClinicalTrials.gov

17. Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

    It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that corre…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    5 in total

    Run by

    Sardocor Corp.

    See if you can join NCT04703842 on ClinicalTrials.gov